top of page
shutterstock_2146510703.jpg
header

NEWS

Impactful technology

CDC_edited.jpg
14351%2520Borrelia%2520recurrentis_edited_edited.png
January 2025
​

HelixBind Named a Phase 3 Winner of the LymeX Diagnostics Prize

by HHS and Steven & Alexandra Cohen Foundation.

shutterstock_1245924046.jpg
December 2024
​

HelixBind announces the award of $9.1 million of non-dilutive funding in 2024

to support validation and commercialization of the company's RaPID diagnostic platform.

Test Tubes
July 2024
​

The China National Intellectual Property Administration (CNIPA) issues HelixBind

patent number 115175765 covering devices and methods for reliably storing and delivering

reagents in a diagnostic system.

Science Lab
MAY 2024
​

USPTO issues HelixBind patent US 11,975,320 covering devices for the direct detection and identification of microorganisms in complex matrices such as blood.

18140 Staph aureus.tif
February 2024

 

Study Demonstrates the Potential of HelixBind’s RaPID/BSI Assay to Accurately Identify Bloodstream Infections Associated with Sepsis in Patients Undergoing Antimicrobial Treatment.

14351%2520Borrelia%2520recurrentis_edite
February 2024

 

HelixBind Named a Phase 2 Winner of the LymeX Diagnostics Prize

by HHS and Steven & Alexandra Cohen Foundation

Closeup of a Petri Dish
December 2023

 

USPTO issues HelixBind patent US 11,840,721 covering

improved methods for detecting microbial infections.

18167 MRSA Staph aureus.tif
December 2023

 

HelixBind announces the award of $6 million of non-dilutive funding in 2023

to advance the company's RaPID diagnostic platform.

​

petri-dish.jpg
august 2023

​

USPTO issues HelixBind patent US 11,713,330 covering methods for ultrasensitive direct detection

of microorganisms, including Borrelia, the causative pathogen of Lyme Disease.

18137 Staphylococcus aureus.tif
February 2023

 

USPTO issues HelixBind patent US 11,590,507 covering reagent carriers for fluidic systems.

​

19059 MRSA Staph aureus.tif
December 2022
​

HelixBind announces $9 million in non-dilutive financing from the NIH in 2022 to support the

development of assays for the direct detection and identification of infections.

14351%2520Borrelia%2520recurrentis_edite
November 2022

 

HelixBind selected as Phase 1 winner of the LymeX Diagnostics Prize competition from

the U.S. Department of Health and Human Services and the Steven & Alexandra Cohen Foundation.

​

21915 E coli.tif
AUGUST 2022
​

USPTO issues HelixBind patent US 11,414,712 covering methods to identify microbial species

direct from complex specimens, such as blood.

shutterstock_1459789826.jpg
August 2022
​

Japanese Patent Office (JPO) issues HelixBind patent JP 7073328 covering multiple aspects

of HelixBind’s sample-to-answer automated device.

​

shutterstock_1245924046.jpg
March 2022
​

Japanese Patent Office (JPO) issues HelixBind patent JP 7046603 covering the company’s method

for the identification of microbial infections directly from human specimens.

​

shutterstock_2506802321.jpg
MARCH 2022
​

The China National Intellectual Property Administration (CNIPA) issues HelixBind

patent number 109414695 covering certain aspects of its integrated fluidic devices for

detecting and identifying of microorganisms.

shutterstock_1596266998.jpg
august 2021
​

USPTO issues HelixBind patent US 11,091,814 covering the methods

to detect bacterial and/or fungal genomic material in a sample.

18133 Staphylococcus aureus (MRSA) bacteria.tif
June 2021
​

HelixBind Awarded $3MM NIH Grant to Support Testing of Its

RaPID Diagnostic Platform for Invasive Infections Associated with Sepsis.

Test Tubes_edited.jpg
AUGUST 2020

 

FDA Grants HelixBind Breakthrough Device Designation for RaPID Sepsis Test.

​

bottom of page